Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

Pneumocystis Jirovecii Infection Clinical Trial

— JIROVECI  

Official title:

Factors Associated With Survival in Patients With a Positive Sample for Pneumocystis Jirovecii at the Strasbourg University Hospital: a Retrospective Study From 2016 to 2018

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06173453
• Other study ID #: 8722
• Status: Recruiting
• Start date: January 1, 2023
• Est. completion date: October 10, 2025

Study information

• Verified date: June 2023
• Source: University Hospital, Strasbourg, France
• Contact: François DANION, MD
• Phone: 33 3 69 55 15 88
• Email: Francois.danion[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.

Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.

Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: October 10, 2025
• Est. primary completion date: August 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Adult patients with a positive respiratory sample for P. jirovecii cared for in Strasbourg University Hospitals between 01/01/2016 and 31/12/2018. Positive samples are defined as a direct examination finding cysts or trophozoites after staining with May-Grunewald-Giemsa and/or Gomori-Grocott, a positive P. jirovecii PCR on sputum, tracheal aspirates or bronchial fluid -alveolar

• Subject not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria:

• Subject having expressed its opposition to the reuse of its data for scientific research purposes.

Related Conditions & MeSH terms

• Infections
• Pneumocystis Infections
• Pneumocystis Jirovecii Infection
• Pneumonia, Pneumocystis

Locations

Country	Name	City	State
France	Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival at six weeks and three months after infection		six weeks after infection